Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | CPT2 | P23786 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20526404 | 1.00 | TDP1 (0.36) | TDP1FFAR1CPT2TSHRALDH1A1 | |
| SCHEMBL1834611 | 1.00 | TDP1 (0.36) | TDP1FFAR1CPT2TSHRALDH1A1 | |
| SCHEMBL27583386 | 1.00 | TDP1 (0.36) | TDP1FFAR1CPT2TSHRALDH1A1 | |
| SCHEMBL1845796 | 1.00 | TDP1 (0.36) | TDP1FFAR1CPT2TSHRALDH1A1 | |
| SCHEMBL20509901 | 1.00 | TDP1 (0.36) | TDP1FFAR1CPT2TSHRALDH1A1 | |
| SCHEMBL6690910 | 1.00 | TDP1 (0.36) | TDP1FFAR1CPT2TSHRALDH1A1 | |
| SCHEMBL3291304 | 1.00 | TDP1 (0.36) | TDP1FFAR1CPT2TSHRALDH1A1 | |
| SCHEMBL4580892 | 0.95 | TDP1 (0.39) | TDP1FFAR1CPT2TSHRALDH1A1 | |
| Fluoride SCHEMBL11519479 | 0.91 | TDP1 (0.36) | TDP1FFAR1CPT2TSHRALDH1A1 | |
| SCHEMBL1615049 | 0.86 | TSHR (0.39) | TDP1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3463330-B1 | DIABETES TREATMENT REGIMENS USING ALPHA, ALPHA-SUBSTITUTED LONG-CHAIN AMPHIPATHIC CARBOXYLATES | SYNDROMEX LTD (IL) | 2022-05-04 | — | — | EP | claimed |
| CN-101129349-A | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | YISSUM RES DEV CO (IL) | 2008-02-27 | — | — | CN | claimed |
| US-10479752-B2 | Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof | SYNDROMEX LTD. (IL) | 2019-11-19 | — | — | US | disclosed |
| US-20140371314-A1 | Deuterated Tetramethyl Dioic Acids, Compositions Comprising Them And Uses Thereof | SYNDROMEX LTD. (IL) | 2014-12-18 | — | — | US | disclosed |
| EP-1001755-B1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNDROME X LTD (IL) | 2011-05-11 | — | — | EP | disclosed |
| CN-101677982-A | Combination therapy, composition and methods for the treatment of cardiovascular disorders | SYNDROMEX LTD | 2010-03-24 | — | — | CN | disclosed |
| US-6303653-B1 | THERAPY OF HEPATOCYTE NUCLEAR FACTOR-4.ALPHA..SUP.1 (HNF-4) MEDIATED DISEASE BY ADMINISTERING CARBOXYLIC ACID OR ITS DERIVATIVE WHICH INHIBITS HNF-4 CONTROLLED TRANSCRIPTION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-10-16 | — | — | US | disclosed |
| EP-1001755-A2 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999000116-A2 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371314-A1 | Deuterated Tetramethyl Dioic Acids, Compositions Comprising Them And Uses Thereof | CYP27A1, GOT2, TXN2 | TDP1 1615/4885FFAR1 515/4885CPT2 44/4885 |
| US-10479752-B2 | Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof | CYP27A1, GOT2, TXN2 | TDP1 1615/4885FFAR1 515/4885CPT2 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.